Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Selvaggi L, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Marforio G, Ballardini M, Lombardi AV, Sorio R, Tumolo S, Costa B, Magni G, Perrone F, Favalli G; SOCRATES and MITO investigators. Pignata S, et al. Among authors: scarfone g. Oncology. 2006;71(5-6):320-6. doi: 10.1159/000108592. Epub 2007 Sep 18. Oncology. 2006. PMID: 17878745
Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.
Bolis G, Favalli G, Danese S, Zanaboni F, Mangili G, Scarabelli C, Tateo S, Valsecchi MG, Scarfone G, Richiardi G, Frigerio L, Melpignano M, Villa A, Parazzini F. Bolis G, et al. Among authors: scarfone g. J Clin Oncol. 1997 May;15(5):1938-44. doi: 10.1200/JCO.1997.15.5.1938. J Clin Oncol. 1997. PMID: 9164205 Clinical Trial.
Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
Bolis G, Scarfone G, Giardina G, Villa A, Mangili G, Melpignano M, Presti M, Tateo S, Franchi M, Parazzini F; Associazione per la Ricerca in Ginecologia Oncologia (ARGO 96) Study Group. Bolis G, et al. Among authors: scarfone g. Gynecol Oncol. 2001 Apr;81(1):3-9. doi: 10.1006/gyno.2001.6151. Gynecol Oncol. 2001. PMID: 11277642 Clinical Trial.
Time since last birth and the risk of ovarian cancer.
Chiaffarino F, Parazzini F, Negri E, Benzi G, Scarfone G, Franceschi S, La Vecchia C. Chiaffarino F, et al. Among authors: scarfone g. Gynecol Oncol. 2001 May;81(2):233-6. doi: 10.1006/gyno.2001.6136. Gynecol Oncol. 2001. PMID: 11330955
92 results